Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygen ase and ornithine decarboxylase and is active against several cancer cell l ines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-perf ormance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 mug/ml. Admini stration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concent ration of 14.7 mug/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min.kg. (C) 2001 Elsevier Science B.V. All rights res erved.